In Therapeutics Letter #1021 we reviewed the inhaled long acting β2 agonist (LABA) indacaterol for chronic obstructive pulmonary disease (COPD). We concluded “There are no proven clinically meaningful benefits in terms of reduction in mortality...
In two previous Therapeutics Letters we presented Clinical Pearls from Prescrire International.1,2 Prescrire is one of a small number of drug bulletins in the world, which reports on prescription drugs and is completely independent of industry influence. The front...
A free webinar on Thursday, 5 July 2018 at 2:00 PM – 3:00 PM EDT = 11:00 AM - 12:00 PM PDT Deprescribing is the planned and supervised process of dose reduction or stopping of medication that may...
Medical Education and Dinner with the Therapeutics Initiative: DEPRESCRIBING (a practical approach and case work presented by Dr. Jessica Otte, MD) WHAT DO WE KNOW ABOUT DRUGS FOR CHF? & SETTING REALISTIC EXPECTATIONS FOR NON-OPIATE DRUGS FOR CHRONIC PAIN (presented by Dr. Aaron...